BiotechTube

ASP1585 + Placebo + Sevelamer hydrochloride

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia, Chronic Kidney Disease

Trial Timeline

Oct 1, 2007 → Sep 1, 2008

NCT ID
NCT00505037

About ASP1585 + Placebo + Sevelamer hydrochloride

ASP1585 + Placebo + Sevelamer hydrochloride is a phase 2 stage product being developed by Astellas Pharma for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00505037. Target conditions include Hyperphosphatemia, Chronic Kidney Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00505037Phase 2Completed

Competing Products

20 competing products in Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
EOS789 + Placebo + RenvelaChugai PharmaceuticalPhase 1
33
DS-2330b PIB + Placebo + Sevelamer + DS-2330b TabletDaiichi SankyoPhase 1
33
ASP1585Astellas PharmaPhase 2
52
the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlacebpKyowa KirinPhase 2
52
KHK7791Kyowa KirinPhase 2
52
KHK7791 + PlaceboKyowa KirinPhase 3
77
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlaceboKyowa KirinPhase 3
77
KHK7791Kyowa KirinPhase 3
77
KHK7791 + PlaceboKyowa KirinPhase 2
52
KHK7791Kyowa KirinPhase 3
77
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HClNovartisPhase 2
52
SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3
77
PA21Kissei PharmaceuticalPhase 3
76
Placebo + Sevelamer Carbonate (GZ419831)SanofiPhase 3
76
Placebo + Sevelamer carbonateSanofiPhase 2
51
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tabletBayerPre-clinical
20
Lanthanum Carbonate (Fosrenol, BAY77-1931)BayerPre-clinical
20
Lanthanum Carbonate (BAY77-1931)BayerPhase 2
49

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85